Silence Therapeutics PLC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Richard Griffiths, a director and significant shareholder of Silence Therapeutics Plc, has sold approximately $87.7 million worth of American Depositary Shares (ADSs) in open market transactions.
NASDAQ
Richard Griffiths and associated entities report a significant sale of Silence Therapeutics Plc ADSs, reducing their beneficial ownership.
NASDAQ
Richard Griffiths, a significant shareholder, has increased his beneficial ownership in Silence Therapeutics Plc to 24.4% through recent open market purchases totaling $2.7 million.
NASDAQ
SCHEDULE 13D/A: Major Shareholder Richard Griffiths Boosts Stake in Silence Therapeutics Amid Share Capital Increase
Richard Ian Griffiths, a significant shareholder in Silence Therapeutics Plc, increased his beneficial ownership to 23.2% through open market purchases totaling $2.4 million, despite a concurrent dilution from the Issuer's increased share capital.
NASDAQ
SCHEDULE 13D/A: Silence Therapeutics Insider Richard Griffiths Boosts Stake with $1.6 Million ADS Purchases
Richard Ian Griffiths, a director and controlling shareholder of Silence Therapeutics Plc, has significantly increased his beneficial ownership in the company through recent open market purchases totaling $1.6 million.
NASDAQ
Richard Ian Griffiths, through various controlled entities, has increased his beneficial ownership in Silence Therapeutics Plc to 20.7% of outstanding ordinary shares following recent open market purchases totaling $3.0 million.